Twenty Years of Active Bacterial Core Surveillance

This program has directly affected public health policies and practices.

[1]  W. Schaffner,et al.  Invasive Haemophilus influenzae Disease in Adults ≥65 Years, United States, 2011 , 2014, Open forum infectious diseases.

[2]  P. Malani,et al.  National burden of invasive methicillin-resistant Staphylococcus aureus infection. , 2014, JAMA.

[3]  S. Schrag,et al.  Two cases of invasive vancomycin-resistant group B streptococcus infection. , 2014, The New England journal of medicine.

[4]  Lee H Harrison,et al.  National burden of invasive methicillin-resistant Staphylococcus aureus infections, United States, 2011. , 2013, JAMA internal medicine.

[5]  S. Madhi,et al.  Considerations for a phase-III trial to evaluate a group B Streptococcus polysaccharide-protein conjugate vaccine in pregnant women for the prevention of early- and late-onset invasive disease in young-infants. , 2013, Vaccine.

[6]  C. Whitney,et al.  Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Children Aged 6–18 Years with Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP) , 2013, MMWR. Morbidity and mortality weekly report.

[7]  L. Rubin,et al.  Infant Meningococcal Vaccination: Advisory Committee on Immunization Practices (ACIP) Recommendations and Rationale , 2013, MMWR. Morbidity and mortality weekly report.

[8]  C. Whitney,et al.  Use of 13‐Valent Pneumococcal Conjugate Vaccine and 23‐Valent Pneumococcal Polysaccharide Vaccine for Adults With Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP) , 2013, MMWR. Morbidity and mortality weekly report.

[9]  M. Kainer,et al.  Fungal infections associated with contaminated methylprednisolone in Tennessee. , 2012, The New England journal of medicine.

[10]  E. Briere,et al.  Haemophilus influenzae Type b Disease and Vaccine Booster Dose Deferral, United States, 1998–2009 , 2012, Pediatrics.

[11]  S. Schrag,et al.  Sentinel versus population-based surveillance of pneumococcal conjugate vaccine effectiveness. , 2012, Bulletin of the World Health Organization.

[12]  W. Schaffner,et al.  Prevention of antibiotic-nonsusceptible Streptococcus pneumoniae with conjugate vaccines. , 2012, The Journal of infectious diseases.

[13]  D. Swerdlow,et al.  Invasive Pneumococcal Disease and Pandemic (H1N1) 2009, Denver, Colorado, USA , 2012, Emerging infectious diseases.

[14]  T. Clark,et al.  Modeling Insights into Haemophilus influenzae Type b Disease, Transmission, and Vaccine Programs , 2012, Emerging infectious diseases.

[15]  Raydel D. Mair,et al.  Current epidemiology and trends in invasive Haemophilus influenzae disease--United States, 1989-2008. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  Kristen Soto,et al.  Changing Disparities in Invasive Pneumococcal Disease by Socioeconomic Status and Race/Ethnicity in Connecticut, 1998–2008 , 2011, Public health reports.

[17]  E. Zell,et al.  Early Estimate of the Effectiveness of Quadrivalent Meningococcal Conjugate Vaccine , 2011, The Pediatric infectious disease journal.

[18]  Updated recommendations for use of meningococcal conjugate vaccines --- Advisory Committee on Immunization Practices (ACIP), 2010. , 2011, MMWR. Morbidity and mortality weekly report.

[19]  C. Whitney,et al.  Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2010, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[20]  W. Schaffner,et al.  Socioeconomic and racial/ethnic disparities in the incidence of bacteremic pneumonia among US adults. , 2010, American journal of public health.

[21]  W. Schaffner,et al.  Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  W. Schaffner,et al.  Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. , 2010, The Journal of infectious diseases.

[23]  W. Schaffner,et al.  Evaluating the potential public health impact of a Staphylococcus aureus vaccine through use of population-based surveillance for invasive methicillin-resistant S. aureus disease in the United States. , 2009, Vaccine.

[24]  V. Nizet,et al.  Point Mutation in the Group B Streptococcal pbp2x Gene Conferring Decreased Susceptibility to β-Lactam Antibiotics , 2008, Antimicrobial Agents and Chemotherapy.

[25]  J. Marc Overhage,et al.  A comparison of the completeness and timeliness of automated electronic laboratory reporting and spontaneous reporting of notifiable conditions. , 2008, American journal of public health.

[26]  C. Whitney,et al.  Emergence of nonvaccine serotypes following introduction of pneumococcal conjugate vaccine: cause and effect? , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  A. Kumar.  Invasive Methicillin-Resistant Staphylococcus aureus Infections in the United States , 2008 .

[28]  Automated detection and reporting of notifiable diseases using electronic medical records versus passive surveillance--massachusetts, June 2006-July 2007. , 2008, MMWR. Morbidity and mortality weekly report.

[29]  Continued shortage of Haemophilus influenzae Type b (Hib) conjugate vaccines and potential implications for Hib surveillance--United States, 2008. , 2008, MMWR. Morbidity and mortality weekly report.

[30]  V. Nizet,et al.  Point Mutation in the Group B Streptococcal pbp 2 x Gene Conferring Decreased Susceptibility to Beta-Lactam Antibiotics Running title : First step pbp 2 x mutation in GBS , 2008 .

[31]  Carolyn M. Greene,et al.  Invasive Group A Streptococcal Infection in Older Adults in Long-term Care Facilities and the Community, United States, 1998–20031 , 2007, Emerging infectious diseases.

[32]  Roberta B Carey,et al.  Invasive methicillin-resistant Staphylococcus aureus infections in the United States. , 2007, JAMA.

[33]  R. Lynfield,et al.  The epidemiology of invasive group A streptococcal infection and potential vaccine implications: United States, 2000-2004. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[34]  C. Richards,et al.  Group a streptococcal disease in long-term care facilities: descriptive epidemiology and potential control measures. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  Revised recommendations of the Advisory Committee on Immunization Practices to Vaccinate all Persons Aged 11-18 Years with Meningococcal Conjugate Vaccine. , 2007, MMWR. Morbidity and mortality weekly report.

[36]  R. H. Albert,et al.  Prevention of perinatal group B streptococcal disease. Revised guidelines from CDC. , 2010 .

[37]  W. Schaffner,et al.  Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study , 2006, The Lancet.

[38]  J. Langley,et al.  Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[39]  J. Hadler,et al.  Gram-positive Rod Surveillance for Early Anthrax Detection , 2005, Emerging infectious diseases.

[40]  C. Whitney,et al.  The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. , 2005, The Journal of infectious diseases.

[41]  R. Lynfield,et al.  Methicillin-resistant Staphylococcus aureus disease in three communities. , 2005, The New England journal of medicine.

[42]  D. Vugia,et al.  SARS and Common Viral Infections , 2004, Emerging infectious diseases.

[43]  Lisa B. Gelling,et al.  Aggregated Antibiograms and Monitoring of Drug-Resistant Streptococcus pneumoniae , 2003, Emerging infectious diseases.

[44]  J. Hughes,et al.  Disease Surveillance and the Academic, Clinical, and Public Health Communities , 2003, Emerging infectious diseases.

[45]  O. Levine,et al.  Risk for Severe Group A Streptococcal Disease among Patients’ Household Contacts , 2003, Emerging infectious diseases.

[46]  Stephanie Schrag,et al.  Prevention of Perinatal Group B Streptococcal Disease Revised Guidelines from CDC , 2002 .

[47]  K. O'Brien,et al.  Prevention of invasive group A streptococcal disease among household contacts of case patients and among postpartum and postsurgical patients: recommendations from the Centers for Disease Control and Prevention. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[48]  A. Schuchat,et al.  Population-based surveillance for postpartum invasive group a streptococcus infections, 1995-2000. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[49]  A. Schuchat,et al.  A population-based comparison of strategies to prevent early-onset group B streptococcal disease in neonates. , 2002, The New England journal of medicine.

[50]  L. Harrison,et al.  Invasive meningococcal disease in adolescents and young adults. , 2001, JAMA.

[51]  Oleg O. Bilukha,et al.  Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2000, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[52]  M. Cetron,et al.  Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. , 2000, The New England journal of medicine.

[53]  Cynthia G. Whitney,et al.  Preventing pneumococcal disease among infants and young children : recommendations of the Advisory Committee on Immunization Practices (ACIP) , 2000 .

[54]  T. Popović,et al.  Antimicrobial resistance of Neisseria meningitidis in the United States, 1997. The Active Bacterial Core Surveillance (ABCs) Team. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[55]  L. Harrison,et al.  Risk of meningococcal infection in college students. , 1999, JAMA.

[56]  A. Levitt,et al.  Preventing Emerging Infectious Diseases: A Strategy for the 21st Century. Overview of the Updated CDC plan. , 1998, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[57]  A. Schuchat,et al.  Prevention of perinatal group B streptococcal disease : a public health perspective , 1996 .

[58]  N. Boe.  Group B streptococcal infections in pregnancy , 1993, The Western journal of medicine.

[59]  G. Pugliese,et al.  Severe Streptococcus pyogenes Infections, United Kingdom, 2003–2004 , 2008, Emerging infectious diseases.

[60]  C. Broome,et al.  American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn: Guidelines for prevention of group B streptococcal (GBS) infection by chemoprophylaxis. , 1992, Pediatrics.

[61]  H. Crowe,et al.  Invasive Haemophilus influenzae disease in adults. , 1987, Archives of internal medicine.